Table 3. Anatomical involvement of new-onset psoriasis (and occurring within 6 months of starting anti-tumour necrosis factor (TNF) therapy in patients 1–13).
| Patient | Age/sex | Treatment | Affected areas | Time to event, months | Improvement on stopping | EULAR responder |
| 1 | 60/F | ETA | Elbows and all over body | 3 | NA | Yes |
| 2 | 63F | ETA | Not stated | 5 | NA | – |
| 3 | 56F | INF | Not stated | 5 | – | – |
| 4 | 64/M | INF | Palmoplantar pustulosis | 6 | NA | Yes |
| 5 | 30/F | INF | Hairline | 6 | NA | Yes |
| 6 | 63/F | ADA | All over, except face | 1 | Yes | No |
| 7 | 47/M | ADA | Palmoplantar pustulosis | 1 | Yes | Yes |
| 8 | 36/F | ADA | Palmoplantar pustulosis | 1 | Yes | No |
| 9 | 62/F | ADA | Back, knees, thighs | 1 | –* | Yes |
| 10 | 58/F | ADA | Elbows, ankle | 2 | NA | Yes |
| 11 | 63F | ADA | Not stated | 3 | NA | – |
| 12 | 66/M | ADA | Right leg and arm | 4 | NA | Yes |
| 13 | 70F | ADA | Not stated | 4 | – | – |
| 14 | 62M | ETA | Not stated | 18 | NA | – |
| 15 | 40F | ETA | Not stated | 23 | NA | – |
| 16 | 56F | ETA | Palmoplantar pustulosis | 24 | Yes | Yes |
| 17 | 33F | ETA | Body and legs | 24 | No | Yes |
| 18 | 66F | INF | Elbows | 12 | No | Yes |
| 19 | 54F | INF | Tops of feet and legs | 12 | NA | Yes |
| 20 | 58F | INF | Legs, upper arms | 18 | No | Yes |
| 21 | 56F | ADA | Palmoplantar pustulosis | 10 | Yes | Yes |
| 22 | 60F | ADA | Legs | 12 | No | Yes |
| 23 | 57F | ADA | Palmoplantar pustulosis | 12 | NA | – |
| 24 | 60F | ADA | Knees | 12 | NA | Yes |
| 25 | 61F | ADA | Arms, lower leg, buttocks, face | 17 | Yes | Yes |
*Treatment stopped, response unknown.
ADA, adalimumab; EULAR, European League Against Rheumatism; ETA, etanercept; INF, infliximab; NA, not applicable, treatment was not stopped